Casma Therapeutics
PrivateLast Round
Grant
Mar 10, 2026
Total Funding Raised
$162.47M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Casma Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Grant round in March 2026.
Casma Therapeutics is a biotechnology company that develops targeted therapies by harnessing the natural cellular process of autophagy to treat lysosomal storage, muscle, inflammatory, and neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Casma Therapeutics Comparables
Compare Casma Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lysoway Therapeutics | 90% | |
| Libra Therapeutics | 89% | |
| Nine Square Therapeutics | 88% |
For institutional investors. Book with your work email.
Casma Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 10, 2026 | ||||
| Series C | Nov 15, 2022 | ||||
| Series B | Sep 10, 2020 | ||||
| Grant | May 29, 2019 | ||||
| Series A | May 3, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Casma Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series C, Series B |
| Mirae Asset | Series C |
| Schroder Adveq | Series B |
| Eventide Funds | Series C, Series B |
| The Chernin Group | Series C, Series B |
| Amgen Ventures | Series C |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
Secured $7.6M in grant funding.
- Jun 9, 2025
CSM-101 is in development for Parkinson's and Gaucher disease.
For institutional investors. Book with your work email.
Casma Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Casma Therapeutics's valuation, stock price, and market status.
Is Casma Therapeutics a public or private company?
Casma Therapeutics is a private company.
What is the current stock price of Casma Therapeutics?
Casma Therapeutics is a private company, so its shares have no public market price. Caplight tracks Casma Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Casma Therapeutics worth (valuation)?
Valuation information for Casma Therapeutics is not publicly available.
Can I buy Casma Therapeutics stock?
Casma Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Casma Therapeutics's last funding round?
Casma Therapeutics's most recent funding round was Grant on March 10, 2026.
Who are the main investors in Casma Therapeutics?
Key investors in Casma Therapeutics include The Column Group, Mirae Asset, Eventide Funds, The Chernin Group, Amgen Ventures.
Will Casma Therapeutics IPO soon?
No public IPO plans have been announced for Casma Therapeutics.
How can I track Casma Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Casma Therapeutics's shares on secondary markets.